Latest period
$198.27M
YoY change
+91.5%
5Y CAGR
+24.5%
Peak year (2021)
$179.75M
Latest annual
$130.66M
Total Equity history chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: $130.66M
Total Equity growth chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: +91.5%
Total Equity history table for Ovid Therapeutics (OVID) from 2014 to 2025
| 2025 | $130.66M | +91.5% | +$62.43M | ||
| 2024 | $68.23M | -22.3% | −$19.57M | ||
| 2023 | $87.80M | -33.6% | −$44.48M | ||
| 2022 | $132.27M | -26.4% | −$47.47M | ||
| 2021 | $179.75M | +312.0% | +$136.11M | ||
| 2020 | $43.63M | -37.7% | −$26.39M | ||
| 2019 | $70.02M | +80.4% | +$31.22M | ||
| 2018 | $38.81M | -53.5% | −$44.63M | ||
| 2017 | $83.44M | +69.3% | +$34.14M | ||
| 2016 | $49.29M | -27.6% | −$18.77M | ||
| 2015 | $68.07M | +1336.6% | +$63.33M | ||
| 2014 | $4.74M | — | — |
- 2025$130.66M+91.5%
- 2024$68.23M-22.3%
- 2023$87.80M-33.6%
- 2022$132.27M-26.4%
- 2021$179.75M+312.0%
- 2020$43.63M-37.7%
- 2019$70.02M+80.4%
- 2018$38.81M-53.5%
- 2017$83.44M+69.3%
- 2016$49.29M-27.6%
- 2015$68.07M+1336.6%
- 2014$4.74M—
Total Equity values are taken from Ovid Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's latest reported total equity is $198.27M. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Ovid Therapeutics (OVID) most recent annual total equity stands at $130.66M (2025) – surged 91.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Ovid Therapeutics total equity compounded at +24.5% per year, with mixed annual results across the window.
Between 2021 and 2025, Ovid Therapeutics total equity declined 27.3%, falling from $179.75M to $130.66M.
$179.75M stands as the all-time-high annual total equity, posted in 2021, against a low of $4.74M during 2014.
Ovid Therapeutics Total Equity by Year
Ovid Therapeutics Total Equity 2025: $130.66M
Ovid Therapeutics posted total equity of $130.66M in 2025, surged 91.5% from 2024.
Ovid Therapeutics Total Equity 2024: $68.23M
In 2024, Ovid Therapeutics reported total equity of $68.23M, declined 22.3% below 2023.
Ovid Therapeutics Total Equity 2023: $87.80M
Ovid Therapeutics total equity in 2023 was $87.80M, plunged 33.6% below 2022.
Ovid Therapeutics Total Equity 2022: $132.27M
2022's total equity for Ovid Therapeutics came in at $132.27M, declined 26.4% below 2021.
Ovid Therapeutics Total Equity 2021: $179.75M
Ovid Therapeutics total equity in 2021 was $179.75M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Total Equity
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation